| Jul 1 |
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
|
| Jun 27 |
With 56% institutional ownership, Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst the big guns
|
| Jun 27 |
Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock?
|
| Jun 20 |
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
|
| Jun 12 |
Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
|
| Jun 12 |
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
|
| May 29 |
Insiders Pour Millions Into These 2 ‘Strong Buy’ Stocks
|
| May 28 |
If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names
|
| May 23 |
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
|
| May 15 |
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
|
